There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

EARNINGS FORECAST: Merck's earnings before interest, taxes, depreciation, amortization and one-off items is forecast to come in at 1.51 billion euros, according to the consensus. The company reported ...

Cyber attacks on companies are no longer a rarity. Volker Buß, CISO at the Merck Group, explains in the CSO interview what is ...

WASHINGTON (AP) — President Donald Trump’s plan to change the pricing model for some medications is already facing fierce ...

Merck & Co., Inc. (MRK) is currently at $79.17, up $3.20 or 4.21% --On pace for largest percent increase since March 27, 2024, when it rose 4.96% --Down 40.46% from its all-time closing high of ...

President Donald Trump announced he will sign an executive order mandating that Americans pay no more for select prescription ...

The latest canine otitis externa medication is the only FDA-approved, 1-dose, in-clinic treatment for Pseudomonas aeruginosa ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...